- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Forma Therapeutics is a biotechnology business based in the US. Forma Therapeutics shares (FMTX) are listed on the NASDAQ and all prices are listed in US Dollars. Forma Therapeutics employs 189 staff and has a trailing 12-month revenue of around $7.4 million.
|Latest market close||$0.00|
|52-week range||$4.95 - $20.28|
|50-day moving average||$17.92|
|200-day moving average||$10.90|
|Wall St. target price||$21.00|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-3.82|
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0 from 2022-11-11
|1 week (2023-03-11)||nan%|
|1 month (2023-02-18)||nan%|
|3 months (2022-12-18)||nan%|
|6 months (2022-09-22)||-100.00%|
|1 year (2022-03-22)||-100.00%|
|2 years (2021-03-22)||-100.00%|
|3 years (2020-03-18)||N/A|
|5 years (2018-03-18)||N/A|
|Revenue TTM||$7.4 million|
|Gross profit TTM||$-125,661,000|
|Return on assets TTM||-21.95%|
|Return on equity TTM||-38.27%|
|Market capitalisation||$1 billion|
TTM: trailing 12 months
We're not expecting Forma Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Forma Therapeutics's shares have ranged in value from as little as $4.95 up to $20.28. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Forma Therapeutics's is -0.9476. This would suggest that Forma Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Forma Therapeutics has bucked the trend.
Forma Therapeutics Holdings, Inc. , a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. As of October 14, 2022, Forma Therapeutics Holdings, Inc.
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
Steps to investing in the Vanguard (VTI) Total Stock Market ETF.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.